Omeros Corporation (NASDAQ:OMER) announced further positive data from its ongoing Phase 2 study of OMS721 evaluating patients with hematopoietic stem cell transplant-associated thrombotic …
Omeros Corporation (NASDAQ:OMER) announced that OMS721 has received orphan drug designation from the FDA for the treatment of Immunoglobulin A (IgA) nephropathy. OMS721 is Omeros’ …
Omeros Corporation (NASDAQ:OMER) announced that it has entered into a senior credit facility with CRG LP, a healthcare-focused investment firm, to retire the company’s …
In a research report released today, Wedbush analyst Liana Moussatos maintained an Outperform rating on shares of Omeros Corporation (NASDAQ:OMER) with a price target …
In a research report issued today, Wedbush analyst Liana Moussatos maintained an Outperform rating on Omeros (NASDAQ:OMER) with a price target of $52, following …
MLV analyst George Zavoico was out pounding the table on Omeros (NASDAQ:OMER) Wednesday, reiterating a Buy rating and a price target of $38.00, which implies …
